1. |
Meraj R, Wikenheiser-Brokamp KA, Young LR. Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med, 2012, 33(5): 486-497.
|
2. |
Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J, 2010, 35(1): 14-26.
|
3. |
Hagaman JT, Schauer DP, McCormack FX, et al. Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective. Am J Respir Crit Care Med, 2010, 181(12): 1376-1382.
|
4. |
Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989, 161(2): 851-858.
|
5. |
Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinasesVEGF receptor 2(Flk1) and VEGF receptor 3(Flt4). Proc Natl Acad Sci USA, 1998, 95(2): 548-553.
|
6. |
Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol, 2004, 28(8): 1007-1016.
|
7. |
Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol, 2005, 29(10): 1356-1366.
|
8. |
Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol, 2006, 4(3): 143-152.
|
9. |
Glasgow CG, Avila NA, Lin JP, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest, 2009, 135(5): 1293-1300.
|
10. |
Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med, 2008, 358(2): 199-200.
|
11. |
Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest, 2010, 138(3): 674-681.
|
12. |
Chang WY, Cane JL, Blakey JD, et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res, 2012, 13: 34.
|
13. |
Radzikowska E, Jaguś P, Skoczylas A, et al. Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases. Pol Arch Med Wewn, 2013, 123(10): 533-538.
|
14. |
Xu KF, Zhang P, Tian X, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM) . Respir Med, 2013, 107(2): 263-268.
|
15. |
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuary studies. Ann Intern Med, 2011, 155(8): 529-536.
|
16. |
Irwig L, Tosteson AN, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med, 1994, 120(8): 667-676.
|
17. |
Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods. Arch Pathol Lab Med, 1998, 122(8): 675-686.
|
18. |
Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol, 2005, 58(9): 882-893.
|
19. |
刘关键, 吴泰相. 诊断性试验的Meta分析——SROC曲线法介绍. 中国循证医学杂志, 2003, 3(1): 41-44.
|
20. |
Xu KF, Lo BH. Lymphangioleiomyomatosis: differential diagnosis and optimal management. Ther Clin Risk Manag, 2014, 10: 691-700.
|
21. |
Hyman MH, Whittemore VH. National institutes of health consensus conference: tuberous sclerosis complex. Arch Neurol, 2000, 57(5): 662-665.
|
22. |
McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanses Respiratory Society clinical practice guidelines: lymphangioleiomymatosis diagnosis and management. Am J Respir Crit Care Med, 2016, 194(6): 748-761.
|